Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 3/20 | 0.31 |
| ▸ | ERN1 | O75460 | 2/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5634854 | 0.90 | MAPK1 (0.34) | CYP3A4MAPK1LMNARAB9ACHRM1 | |
| SCHEMBL9198854 | 0.76 | CYP3A4 (0.36) | CYP3A4MAPK1LMNARAB9ACHRM1 | |
| SCHEMBL9192901 | 0.75 | LMNA (0.35) | CYP3A4MAPK1LMNARAB9ACHRM1 | |
| SCHEMBL16391486 | 0.72 | LMNA (0.33) | CYP3A4MAPK1LMNARAB9A | |
| SCHEMBL21664601 | 0.72 | CYP1A2 (0.40) | LMNACHRM1TSHRPOLB | |
| SCHEMBL16372005 | 0.72 | SMN1; SMN2 (0.43) | CYP3A4MAPK1LMNARAB9ACHRM1 | |
| SCHEMBL2985134 | 0.71 | LMNA (0.46) | CYP3A4MAPK1LMNARAB9ACHRM1 | |
| SCHEMBL6754852 | 0.71 | SMN1; SMN2 (0.47) | CYP3A4MAPK1LMNARAB9ATSHR | |
| SCHEMBL2839456 | 0.71 | LMNA (0.35) | CYP3A4MAPK1LMNARAB9ACHRM1 | |
| SCHEMBL8924794 | 0.71 | LMNA (0.42) | CYP3A4MAPK1LMNARAB9ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240222705-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM BATTERY | ZHANGJIAGANG GUOTAI-HUARONG NEW CHEMICAL MATERIALS CO., LTD. (CN) | 2024-07-04 | — | — | US | claimed |
| EP-4391135-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM BATTERY | Zhangjiagang Guotai-Huarong New Chemical Materials Co., Ltd (CN) | 2024-06-26 | — | — | EP | claimed |
| CN-115911544-B | Nonaqueous electrolyte and lithium battery | 张家港市国泰华荣化工新材料有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-115911544-A | Non-aqueous electrolyte and lithium battery | 张家港市国泰华荣化工新材料有限公司 | 2023-04-04 | — | — | CN | claimed |
| WO-2023020314-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM BATTERY | 张家港市国泰华荣化工新材料有限公司 | 2023-02-23 | — | — | WO | claimed |
| US-20240222705-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM BATTERY | ZHANGJIAGANG GUOTAI-HUARONG NEW CHEMICAL MATERIALS CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240222705-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM BATTERY | ZHANGJIAGANG GUOTAI-HUARONG NEW CHEMICAL MATERIALS CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240222705-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM BATTERY | ZHANGJIAGANG GUOTAI-HUARONG NEW CHEMICAL MATERIALS CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| EP-4391135-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM BATTERY | Zhangjiagang Guotai-Huarong New Chemical Materials Co., Ltd (CN) | 2024-06-26 | — | — | EP | disclosed |
| EP-4391135-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM BATTERY | Zhangjiagang Guotai-Huarong New Chemical Materials Co., Ltd (CN) | 2024-06-26 | — | — | EP | disclosed |
| CN-115911544-B | Nonaqueous electrolyte and lithium battery | 张家港市国泰华荣化工新材料有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-115911544-A | Non-aqueous electrolyte and lithium battery | 张家港市国泰华荣化工新材料有限公司 | 2023-04-04 | — | — | CN | disclosed |
| WO-2013149996-A9 | SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS | ALMIRALL, S.A. (ES) | 2014-02-20 | — | — | WO | disclosed |
| WO-2013149996-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS | ALMIRALL, S.A. (ES) | 2013-10-10 | — | — | WO | disclosed |
| US-20070161619-A1 | Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161619-A1 | Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161619-A1 | Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| CN-1946721-A | Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof | ASTRAZENECA AB (SE) | 2007-04-11 | — | — | CN | disclosed |
| EP-1716146-A1 | PYRROLOQUINOLINE AND PIPERIDOQUINOLINE DERIVATIVES, PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USES THEREOF | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005075476-A1 | PYRROLOQUINOLINE AND PIPERIDOQUINOLINE DERIVATIVES, PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161619-A1 | Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof | OPRL1, OPRD1, OPRK1 | CYP3A4 316/4885MAPK1 3729/4885LMNA 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.